Nascent Biotech, Inc. (OTCMKTS:NBIO) Sees Large Increase in Short Interest

Nascent Biotech, Inc. (OTCMKTS:NBIO) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 16,500 shares, an increase of 16,400.0% from the December 31st total of 100 shares. Based on an average trading volume of 293,000 shares, the days-to-cover ratio is currently 0.1 days.

Nascent Biotech Stock Performance

Shares of OTCMKTS NBIO remained flat at $0.00 during mid-day trading on Friday. Nascent Biotech has a 1-year low of $0.00 and a 1-year high of $0.19. The company has a 50 day simple moving average of $0.04 and a 200-day simple moving average of $0.05.

About Nascent Biotech

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.